Introduction {#s1}
============

The concept of oxygen as a therapeutic agent was first recognised in the late 18th century by Thomas Beddoes, the father of respiratory therapy \[[@C1]\]. It was not until the early 20th century that clinical values of oxygen were better appreciated with the discoveries of its physiological effects. Domiciliary oxygen therapy was then pioneered in the 1950s by Cotes in the UK and Barach in the USA, with the development of portable delivery systems \[[@C2], [@C3]\]. Today, domiciliary oxygen therapy is commonly prescribed for patients with chronic hypoxaemia. The use of domiciliary oxygen therapy has been increasing worldwide in recent years, accounting for substantial health expenditure. The national incidence of domiciliary oxygen therapy in Sweden increased from 3.9 to 14.7 per 100 000 population between 1987 and 2015 \[[@C4]\]. In Australia, the total annual costs for domiciliary oxygen therapy were estimated to be AUD31 million in 2005, excluding indirect clinical costs associated with serial assessment, patient education and support \[[@C5]\]. It is estimated that Medicare expenditures for domiciliary oxygen therapy increased from USD1.7 billion in 1997 to USD2.9 billion in 2008 in the USA \[[@C6], [@C7]\]. While correcting hypoxaemia may confer physiological benefits, the effects of supplemental oxygen on oxidative stress responses remain unclear \[[@C8]--[@C11]\]. More importantly, patients have described a range of physical difficulties and psychological burden with using domiciliary oxygen therapy \[[@C12]--[@C14]\]. Globally, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) are the two most common indications for domiciliary oxygen therapy \[[@C4], [@C15]--[@C17]\]. Despite both diseases sharing clinical features of dyspnoea and exercise limitations, there are marked differences in their prevalence, pathophysiology and natural history. Herein, we review and contrast the epidemiology of hypoxaemia and current evidence regarding the role of domiciliary oxygen therapy in COPD and ILD.

Epidemiology and significance of hypoxaemia in COPD and ILD {#s2}
===========================================================

The prevalence of hypoxaemia among patients with COPD and ILD remains unclear. This is in part due to the lack of standardised definitions and test modalities for describing different types of hypoxaemia, including resting, exertional and nocturnal hypoxaemia. In addition, prevalence rates of hypoxaemia vary depending on the selected study population and disease severity. Nevertheless, current literature suggests that hypoxaemia is a significant feature in both COPD and ILD.

Resting hypoxaemia is a marker of advanced disease stages for chronic lung diseases. It is commonly defined as resting arterial oxygen tension (*P*~aO~2~~) ≤55 mmHg or 56--59 mmHg with evidence of end-organ damage (cor pulmonale, polycythaemia and/or pulmonary hypertension). Longitudinal data from the Swedish National Register of COPD reported a resting hypoxaemia prevalence of 1.4% \[[@C18]\]. Of those with moderate-to-severe COPD, 7% of patients developed resting hypoxaemia after follow-up for a median of 5 years \[[@C19]\]. There is a paucity of studies evaluating the epidemiology of resting hypoxaemia in ILD in the literature. Recent large randomised controlled trials in idiopathic pulmonary fibrosis, the most common form of ILD, reported that 21--28% of trial participants were prescribed supplemental oxygen therapy \[[@C20], [@C21]\]. However, these reported rates included any use of domiciliary oxygen therapy, without differentiating resting from isolated exertional hypoxaemia. A recent retrospective study of 400 patients at Australian specialised ILD clinics reported a resting hypoxaemia prevalence of 3.5% \[[@C22]\].

Definitions of exertional hypoxaemia vary widely in clinical trials, including a nadir arterial oxygen saturation measured by pulse oximetry (*S*~pO~2~~) of ≤88% \[[@C23]--[@C26]\] and a decrease in *S*~pO~2~~ of ≥4% with or without a nadir *S*~pO~2~~ of \<90% \[[@C27]--[@C31]\]. Regardless of the definitions used, exertional hypoxaemia is common in patients with COPD and ILD. The prevalence of exertional hypoxaemia ranges from 29% to 39% for patients with moderate-to-severe COPD \[[@C25], [@C26]\]. In unselected groups of patients with ILD, 49--54% experience exertional hypoxaemia \[[@C22], [@C32]\]. Consistent with clinical observation, exertional hypoxaemia is more common in patients with ILD compared with those with COPD. With similar degrees of respiratory physiology impairment, patients with ILD experience more severe exertional hypoxaemia than those with COPD \[[@C32]\]. Nevertheless, exertional hypoxaemia is an important prognostic factor for both COPD \[[@C25], [@C33]\] and ILD populations \[[@C23], [@C34], [@C35]\].

The prevalence of nocturnal hypoxaemia in patients with COPD and ILD varies from 27% to 70% \[[@C36]--[@C39]\] and 36% to 57% \[[@C40]--[@C43]\], respectively. In addition to the variations in criteria used to define nocturnal hypoxaemia in these studies, the presence of coexisting sleep disordered breathing may also impact on its prevalence. In both conditions, nocturnal hypoxaemia is only loosely related to daytime resting or exertional hypoxaemia and does not correlate with the degree of lung function impairment \[[@C37], [@C39], [@C41]\]. There have been studies that suggest a potential association of nocturnal hypoxaemia with pulmonary hypertension in patients with COPD and ILD \[[@C41], [@C43]--[@C45]\]. However, the presence of sleep disordered breathing, a common comorbidity in patients with both conditions \[[@C46]--[@C48]\], was not evaluated in the majority of these studies. The prevalence and prognostic significance of nocturnal hypoxaemia without sleep disordered breathing for both conditions are uncertain.

Long-term oxygen therapy in COPD and ILD {#s3}
========================================

Long-term oxygen therapy (LTOT) is typically prescribed to be used for at least 15--18 h per day for patients with resting hypoxaemia. It is a well-established intervention in patients with COPD and resting hypoxaemia. Therapeutic benefits of LTOT were reported in two pivotal randomised controlled trials published \>30 years ago: the Nocturnal Oxygen Therapy Trial (NOTT) and the Medical Research Council (MRC) trial \[[@C49], [@C50]\]. Both trials studied patients with stable severe COPD and significant resting hypoxaemia, as defined previously. In the MRC trial, patients randomised to nocturnal oxygen supplementation for at least 15 h daily had improved survival compared with the control group at 5-year follow-up (55% *versus* 33%; p\<0.05). The NOTT trial compared the effects of continuous oxygen therapy against nocturnal oxygen therapy for 12 h. Patients who used continuous oxygen therapy consistently had better prognosis at 1-year and 2-year follow-up. These studies provide evidence for survival benefit with LTOT in a subgroup of patients with COPD and highlighted the importance of usage duration for LTOT.

On the contrary, the beneficial effects of LTOT have not been shown in patients with COPD and moderate resting or exertional hypoxaemia. Two trials in the 1990s and 2000s revealed no significant differences in survival between treated and untreated groups \[[@C51], [@C52]\]. Arguably, both trials were underpowered to detect survival differences. The US-based Long-Term Oxygen Treatment Trial (LOTT), a multicentre unblinded randomised controlled trial of oxygen for patients with COPD, was completed in 2015 \[[@C53]\]. There was no significant difference between treatment and control groups in time to hospital admission or death and other outcomes, including health-related quality of life and symptoms. The LOTT trial encountered many challenges, particularly study recruitment, which resulted in trial design amendments over the course of 5 years. Study eligibility criteria were extended to include patients with moderate exertional desaturation only, in addition to those with moderate resting hypoxaemia. The primary outcome for this trial was also changed from all-cause mortality to a composite primary outcome (time to death or first hospitalisation for any cause). Recruitment challenges faced by the LOTT trial reflect the strong belief in oxygen therapy among healthcare professionals and patients, despite the lack of evidence in this area. Results from the LOTT trial confirmed the lack of efficacy for LTOT in patients with stable COPD and moderate hypoxaemia.

In comparison with the landmark trials of LTOT in COPD, there is a lack of high-quality studies evaluating the efficacy of LTOT in patients with ILD. The only small multicentre controlled study of LTOT conducted in 1988 by Braghiroli and Donner remains unpublished, although some data have been reported in a Cochrane review \[[@C54]\]. In this study, 62 patients with clinically stable ILD and resting hypoxaemia, defined as *P*~aO~2~~ between 45 and 60 mmHg, were recruited. The majority of patients (79%) had idiopathic pulmonary fibrosis as defined at the time. There was no significant difference in mortality between the treated and untreated groups, with mortality rates of 91% for both groups after 3 years. The observed high mortality rates are consistent with findings from retrospective studies of patients with ILD who were on LTOT, showing 50% of patients died within 1 year of commencing LTOT or home ventilation \[[@C55]--[@C57]\]. Despite a lack of evidence, LTOT remains widely accepted for use in patients with ILD and resting hypoxaemia.

Ambulatory oxygen therapy in COPD and ILD {#s4}
=========================================

Ambulatory oxygen therapy (AOT) involves the use of a portable oxygen delivery device during exercise or activities of daily living. This therapy can be prescribed as a stand-alone intervention for patients with isolated exertional hypoxaemia or as a supplement to a stationary oxygen concentrator for LTOT. The range of portable oxygen delivery devices for ambulatory use has expanded from compressed oxygen cylinders in the 1950s \[[@C2], [@C3]\] and liquid oxygen systems in the 1960s \[[@C58]\] to portable oxygen concentrators, first introduced in the 1990s and commercially available since the 2000s \[[@C59]--[@C61]\]. Compressed oxygen cylinders are still the most widely used source of AOT globally, with liquid oxygen systems and portable oxygen concentrators being used in some countries.

The therapeutic role of AOT in COPD and ILD remains controversial. The effects of supplemental oxygen during activities in patients with COPD and ILD have been evaluated during in-laboratory exercise tests and in clinical trials. Various exercise tests, including walk tests, treadmill tests and cycle ergometry, have been used for in-laboratory assessments. For both diseases, supplemental oxygen therapy has consistently been shown to improve exercise performance during in-laboratory tests, with some reporting a reduction in exertional dyspnoea \[[@C62], [@C63]\]. In addition to small study populations, most of these in-laboratory assessment studies had inadequate study design with a lack of blinding and randomisation. Furthermore, it is not possible to translate these findings from in-laboratory assessment studies into daily life given the differences in exercise intensity and functional requirements.

A systematic review of four randomised placebo-controlled trials of AOT in patients with COPD concluded that oxygen improved exertional dyspnoea, without survival benefit or enhanced exercise capacity \[[@C64]\]. The review included patients without significant resting hypoxaemia, defined as meeting the criteria for LTOT, with the duration of intervention varying between 2 and 12 weeks. Although the dyspnoea and fatigue domains of health-related quality of life, measured using the Chronic Respiratory Questionnaire, statistically favoured AOT, the improvement did not reach the threshold for clinical significance. The recent LOTT trial showed no beneficial effects in health-related quality of life and functional status with nocturnal and AOT in COPD patients with moderate exertional desaturation, defined as a fall in *S*~pO~2~~ to \<80% for ≥5 min and \<90% for ≥10 s \[[@C53]\]. In a parallel-group double-blinded randomised placebo-controlled trial by M[oore]{.smallcaps} *et al.* \[[@C65]\], there were no significant differences in dyspnoea, mental wellbeing, health-related quality of life or functional status between intervention and placebo groups. However, only 50 patients included in this study demonstrated exertional desaturation to ≤88% during 6-min walk tests at baseline. Randomised trials of patients with COPD on LTOT revealed no beneficial effects from adding AOT to stationary concentrator use \[[@C66]--[@C68]\]. It is important to note that there was minimal to little increment in oxygen usage duration with the provision of AOT, regardless of the delivery systems provided for AOT.

The only published randomised prospective trial in patients with ILD, evaluating longer-term effects of AOT, delivered *via* compressed oxygen cylinders, is the Ambulatory Oxygen in Fibrotic Lung Disease (AmbOx) trial \[[@C69]\]. The AmbOx trial was a multicentre randomised controlled crossover trial in the UK comparing the effects of AOT with no AOT during activities in patients with fibrotic ILD and isolated exertional desaturation. This trial randomly assigned 84 participants to two 2-week periods of AOT or no AOT, without a washout period in between. AOT significantly improved both the "Breathlessness and activity" and "Chest symptoms" domains of the King\'s Brief ILD Questionnaire (K-BILD), but not the "Psychological" domain. Although total K-BILD score, a measure of overall health-related quality of life, was improved with AOT (difference 3.7 points; p\<0.0001), the minimal clinically important difference (MCID) of 5 points was not met \[[@C70]\]. However, the MCID was met for the "Breathlessness and activity" domain (difference 8.6 points; MCID of 7 points), the domain most likely to be affected by an intervention used only during activity. The majority of patients (n=51 (67%)) in this study chose to continue using AOT at study end. Younger age, increased disease severity and improved dyspnoea on patients' global assessment were associated with the decision for continued use of AOT. In the AmbOx trial, the effects of ambulatory oxygen were evaluated over a period of 2 weeks only. Future studies are needed to assess the longer-term effects of oxygen on patient quality of life, activity levels, health resource utilisation and physiological parameters.

Most of the aforementioned studies on AOT were conducted using compressed oxygen cylinders. In recent years, the performance of selected portable oxygen concentrators has been shown to compare favourably with that of compressed oxygen cylinders in in-laboratory assessment studies of patients with COPD and ILD \[[@C71], [@C72]\]. Compressed oxygen cylinders were the least favoured delivery device in both studies. It is noteworthy that the maximum oxygen delivery capacity of currently available portable oxygen concentrators and compressed oxygen cylinders is limited. The severe levels of exertional desaturation experienced by patients with ILD may not be completely corrected using either type of delivery system \[[@C72]\].

While AOT may have a role in patients with ILD and isolated exertional hypoxaemia, it is clear that it does not improve clinical outcomes in patients with COPD. From the lessons learned in COPD, data from the single assessment studies in ILD need to be interpreted carefully. Although the AmbOx trial has advanced current knowledge regarding the role of AOT in ILD, long-term effects of AOT remain unknown. The development of novel delivery devices enabling greater AOT adherence may impact on its therapeutic potential, and are needed to meet the efficacy, practicality and safety requirements for ambulatory use. In addition to having high oxygen production capabilities, such devices would need to be safe, self-sustaining, lightweight, ergonomic, unobtrusive and affordable.

Nocturnal oxygen therapy in COPD and ILD {#s5}
========================================

The effects of nocturnal oxygen therapy in patients with COPD and ILD are unclear. There have been three small randomised controlled trials of nocturnal oxygen therapy in COPD, with intervention periods from 6 weeks to 3 years \[[@C73]--[@C75]\]. The presence of sleep disordered breathing was investigated using either polysomnography or overnight oximetry in these studies. In 76 patients with COPD and coexisting mild-to-moderate resting hypoxaemia as well as nocturnal desaturation, C[haouat]{.smallcaps} *et al.* \[[@C74]\] found nocturnal oxygen therapy induced no change in survival or requirement for LTOT after 2 years of follow-up. Similarly, studies in patients with isolated nocturnal hypoxaemia also failed to demonstrate any improvement in survival or health status with nocturnal oxygen therapy \[[@C73], [@C75]\]. The effects of nocturnal oxygen on pulmonary haemodynamic measurements in these studies are conflicting. C[haouat]{.smallcaps} *et al.* \[[@C74]\] reported no impacts on the evolution of pulmonary vascular measurements with the use of nocturnal oxygen therapy. In contrast, F[letcher]{.smallcaps} *et al.* \[[@C73]\] found a significant downward trend in pulmonary arterial pressure in patients treated with nocturnal oxygen therapy compared with those who received sham treatment. The effects of nocturnal oxygen therapy in patients with ILD are yet to be explored.

Translating evidence into clinical practice {#s6}
===========================================

Based on the evidence from the landmark trials in COPD, current clinical guidelines from different regions have consistently recommended LTOT for both COPD and ILD patients with significant resting hypoxaemia, defined as resting *P*~aO~2~~ ≤55 mmHg (7.3 kPa) or 56--59 mmHg (7.4--8.0 kPa) with evidence of chronic hypoxaemia (cor pulmonale, polycythaemia and/or pulmonary hypertension) \[[@C76]--[@C82]\].

In contrast, recommendations for AOT in patients with COPD and ILD vary substantially across different regions. The British Thoracic Society recommends prescription of AOT only to patients who are on LTOT and who have preserved outdoor mobility \[[@C79]\]. The Thoracic Society of Australia and New Zealand guideline has a strong recommendation for supplementing stationary concentrator use with AOT in patients using LTOT in order to maximise the number of hours spent with hypoxaemia reversed, while acknowledging the level of evidence is very low \[[@C80]\]. For patients who are ineligible for LTOT with isolated exertional hypoxaemia, there is a weak recommendation for prescribing AOT if demonstrable improvements are observed in symptoms or exercise capacity during a blinded assessment with oxygen *versus* air. In addition to its use in those who demonstrate an improved exercise capacity during exercise testing, the German Society for Pneumology and Respiratory Medicine guideline also recommends AOT in patients with moderate resting hypoxaemia (defined as resting *P*~aO~2~~ ≤60 mmHg) who experience significant exertional hypoxaemia (defined as a reduction of *P*~aO~2~~ ≥5 mmHg during ergometric assessment) \[[@C82]\]. Some national societies recommend consideration of AOT in patients with ILD who experience dyspnoea or exercise limitation due to exertional desaturation \[[@C76], [@C81]\].

Similarly, there are inconsistent guideline recommendations for the use of nocturnal oxygen therapy. The British Thoracic Society recommends against nocturnal oxygen therapy for patients with both COPD and ILD, unless they meet the eligibility criteria for LTOT \[[@C79]\]. In contrast, the Thoracic Society of Australia and New Zealand guideline states that nocturnal oxygen therapy may be considered in patients with chronic lung diseases and nocturnal desaturation (defined as *S*~pO~2~~ ≤88% for more than one-third of the night), particularly in the presence of hypoxia-related sequelae \[[@C80]\].

Heterogeneity in current guideline recommendations for AOT and nocturnal oxygen therapy reflects the lack of high-level evidence in this area. In addition, variation in funding availability and preconceptions of oxygen therapy from both physicians and patients have a significant impact on clinical practice. Current domiciliary oxygen therapy guidelines were written between 2008 and 2016. It is important that the latest evidence from the LOTT and AmbOx trials be incorporated into new guidelines and translated into clinical practice to improve patient care. Despite the consistent recommendation regarding LTOT, adherence to prescribing guidelines is poor, with marked variation across different regions, ranging from 14% to 63% \[[@C15], [@C83]--[@C86]\]. In order to translate evidence into clinical practice, it will be essential for national and international societies to work together with health bureaucracies to update and implement clinical guidelines, provide educational resources and monitor prescriber adherence.

Conclusions {#s7}
===========

Despite \>60 years of the therapeutic application of oxygen, our understanding of the appropriate clinical use of domiciliary oxygen therapy remains limited. It has taken \>30 years to prove the inefficacy of domiciliary oxygen therapy in patients with COPD and moderate hypoxaemia after the initial confirmed therapeutic benefits in those with severe resting hypoxaemia. The role of supplemental oxygen therapy for patients with COPD and ILD with exertional or nocturnal hypoxaemia only remains uncertain. Despite a paucity of evidence, prescription of supplemental oxygen therapy is common in both COPD and ILD, and is associated with significant healthcare costs. Further studies are currently underway to clarify the therapeutic potentials of various types of domiciliary oxygen therapy in COPD and ILD ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifiers: NCT01044628, NCT02551068, NCT03441204 and NCT03737409; [Australian New Zealand Clinical Trials Registry](http://www.anzctr.org.au/) identifier: ACTRN12617000054314). Given that this is an evolving area, timely updates of clinical guidelines and prescribing criteria for domiciliary oxygen therapy are crucial to incorporate new evidence into practice for optimal patient outcomes.
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